Recurrence of Cutaneous T-Cell Lymphoma Post Viral Vector COVID-19 Vaccination

The document reported two cases of cutaneous T-cell lymphoma (CTCL) recurrence following COVID-19 vaccination with the viral vector vaccine Vaxzevria (Oxford/AstraZeneca). A 60-year-old male with folliculotropic mucosis fungoides and a 73-year-old female with early-stage mucosis fungoides and lymphomatoid papulosis experienced disease reactivation after vaccination. The study speculated that the vaccine might have triggered CD30 expression, leading to T-cell exhaustion and disease recurrence, although it acknowledged the possibility of coincidence due to the waxing and waning nature of these conditions. The document highlighted the need for further research on vaccine safety and efficacy in immunocompromised patients.